To the Editor: We read with great interest the recent article published in the American Journal of Gastroenterology by Edward W. Lee et al. [1] . This retrospective study identified that coil-assisted retrograde transvenous obliteration (CARTO) was an effective and safe treatment option for overt hepatic encephalopathy (HE) due to spontaneous portosystemic shunt (SPSS). We appreciate the novel innovation; however, several issues about the application of CARTO in the current study may need to be discussed here.
First, clinical success rate of CARTO in this article is not more effective than that of balloon-occluded retrograde transvenous obliteration (BRTO) described before [2] (91% (39/43) vs 100% (17/17)). This might be associated with the use of gelfoam slurry as the embolic material. Kim et al. [3] proposed that gelfoam could not offer the permanent endothelial destruction and thrombosis as seen with sclerosants. Actually, the low toxic sclerosant used in our study [4] , lauromacrogol, provided higher complete obliteration rate of 100% (31/31).
Second, based on the number of coils used during the procedure, CARTO is much more costlier than BRTO because coils are very expensive. The average number of coils used in this paper is 13.7 (range: 4-35), which could be a heavy economic burden for the patient. Relatively, a single intravascular balloon brings much more economic benefit.
Finally, the average procedure time is longer for CARTO than BRTO due to deployment of multiple coils versus placement of a single balloon for reduction of blood flow in the shunt. Indeed, the average procedure time is 2.1 h in the article and 2.82 h in another paper [5] by the same author using CARTO for treatment of gastric varices. However, the average procedure time in our BRTO study [4] was 1.6 h (n = 31, range: 40 min-3.0 h). Longer procedure time means more exposure of radiation for both the patient and operator, and more risk of procedure-related complications.
In summary, CARTO remains challenges including relatively low cost-effectiveness and long procedure time. Actually, CARTO is advantageous in situations like larger shunt size and severe vessel tortuosity not available for placement of the balloon [6] . BRTO with low toxic sclerosant like lauromacrogol, appears suitable as the first line choice for treatment of patients with refractory HE and SPSS. Compared studies regarding BRTO and CARTO with larger sample size are needed for further conclusion.
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